cybrsage
New member
I have been researching MK-677 and I found two different human study groups. The first is with seniors and it was stopped short due to heart issues it could potentially cause. The second was with children and it was a smashing success. Apparently, if you are basically healthy, you have no worries about the heart issues...if you are old and frail, stay away from MK-677. As bodybuilders, I think we all fall into the first category as basically healthy (or very healthy, etc).
I have edited down the quotes to make them easier to read:
I have edited down the quotes to make them easier to read:
http://www.aggjournal.com/article/S0167-4943(10)00253-0/abstractMost elderly patients admitted for hip fracture suffer functional decline. Previous studies with MK-0677 in hip fracture patients suggested possible benefits to functional recovery. This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 or placebo.
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood. At 24-weeks, the mean stair climbing power increased by 12.5 W in the MK-0677 group compared with placebo. The MK-0677 group experienced fewer falls during the study compared to placebo. Levels of IGF-1 in treated patients increased by 51.4ng/ml performance measures. Trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients.
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I... - PubMed - NCBIIbutamoren mesylate (MK-0677), an orally active nonpeptide growth hormone (GH) secretagogue, stimulates GH release through a pituitary and hypothalamic receptor that is different from the GH-releasing hormone receptor. We evaluated the safety and tolerability and the GH-insulin-like growth factor (IGF) responses to two dosages of oral ibutamoren mesylate given to children with GH deficiency for 7 to 8 days. The patients, 18 prepubertal children (15 male, 3 female) with idiopathic GH deficiency, had a chronologic age of 10 - 11 years.
The children were assigned as follows to one of three treatment groups with ibutamoren mesylate: 0.2 mg/kg per day for 7 days (days 1-7 or 8-14) and matching placebo for the alternate 7 days (groups I and II, respectively) or 0.8 mg/kg per day for 7 days (days 8-14, group III). On day 15 all patients received an 0.8-mg/kg dose of ibutamoren mesylate. Patients in groups I and II were studied first to assess safety at the low dose before advancement to the high dose. Hormonal profiles were evaluated on day -1 (baseline) and day 15, and the results were expressed as the change from baseline within each group.
After administration of ibutamoren mesylate 0.8 mg/kg for 8 days (group III), the median increases (on day 15) from baseline were as follows: 3.8 microg/L for serum GH peak concentration , 12 microg/L for serum IGF-I, and 0.4 microg/L for serum IGF-binding protein 3 (IGFBP-3). There was no change in serum prolactin, glucose, triiodothyronine, thyroxine, thyrotropin, peak serum cortisol, and insulin concentrations or 24-hour urinary free cortisol after administration of 0.8 mg/kg per day of ibutamoren mesylate for 8 days. We conclude that short-term administration of ibutamoren mesylate can increase GH, IGF-I, and IGFBP-3 levels in some children with GH deficiency.